Systemic sclerosis & Raynaud's
Adopting a Standard of Care for Systemic Sclerosis: The Mayo Clinic Experience
Authors' conclusion
Implementation of autoHCT for severe SSc in a multidisciplinary care model was associated with favorable survival and meaningful improvement in skin disease, with acceptable toxicity.
Study context
- Population
- Consecutive patients with severe systemic sclerosis (SSc) with progressive disease despite standard immunosuppressive therapy undergoing autologous hematopoietic cell transplantation (autoHCT), April 1, 2020–December 31, 202380% female
- Participants
- 25 patients
- Outcome
- OS and EFS
- Follow-up
- 2 years
Methodological detailsconsecutive patients, single-centre
- Consecutive patients
- Single-centre
Main finding
As reported in the abstract
Two-year overall survival (OS)
91.67%
95% CI 81.25–100.0
Two-year event free survival (EFS)
74.51%
95% CI 58.78–94.45
Observational data: associations, not effects.
Secondary outcomes
Two-year cumulative incidence of relapse · 2 years
- Cumulative incidence of relapse
- 23.93% (95% CI 4.27 −43.59)
Two-year nonrelapse mortality (NRM) · 2 years
- NRM
- 8.33% (95% CI 2.97-19.64)
Modified Rodnan Skin Score · day +90 and +180
- Significant improvement at day +90 and +180
- P < 0.05
Pulmonary function
- Pulmonary function stabilized
Safety
Infectious complications, primarily viral reactivations
- Infectious complications
- 56%
Original publication
Adopting a Standard of Care for Systemic Sclerosis: The Mayo Clinic Experience. Arthritis Care Res (Hoboken). Published 31 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →